- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05929664
Cemiplimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery
Neoadjuvant REGN2810 (Cemiplimab) in Cutaneous Basal Cell Carcinoma of the Head and Neck
Study Overview
Status
Conditions
Detailed Description
PRIMARY OBJECTIVE:
I. To assess treatment response of locally advanced basal cell carcinoma (BCC) of the head and neck (BCCHN) in the neoadjuvant, presurgical setting.
SECONDARY OBJECTIVES:
I. To assess functional organ preservation with neoadjuvant Cemiplimab therapy. II. To assess pathologic response. III. To assess safety of neoadjuvant therapy. IV. To assess changes in quality of life.
EXPLORATORY OBJECTIVE:
I. To assess treatment-related changes in the immune microenvironment related to functional changes in immune cell composition.
OUTLINE:
Patients receive cemiplimab intravenously (IV) on study. Patients undergo computed tomography (CT) scans and collection of blood samples throughout the trial.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Joseph Curry, MD
- Phone Number: 215-955-6760
- Email: Joseph.Curry@jefferson.edu
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Recruiting
- Thomas Jefferson University Hospital
-
Contact:
- Joseph Curry, MD
- Phone Number: 215-955-6760
- Email: Joseph.Curry@jefferson.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Pathologically confirmed, locally-advanced BCC of the head and neck requiring greater than 30% auriculectomy, rhinectomy, upper or lower lip resection, orbital exenteration (due to lid or orbital involvement), facial nerve sacrifice or Brigham and Women's stage 2b or 3 disease of head and neck
* Tumor Specific Inclusion Criteria
- Tumor Site: Nose; Inclusion criteria: >= 30% involvement
- Tumor Site: Lips; Inclusion criteria: >= 30% involvement
- Tumor Site: Ear; Inclusion criteria: >= 30% involvement
- Tumor Site: Eyelid; Inclusion criteria: >= 50% involvement, American Joint Committee on Cancer (AJCC) stage 3
- Tumor Site: Facial Nerve; Inclusion criteria: Clinical determination of need for sacrifice by treating surgeon
- Tumor Site: Orbit; Inclusion criteria: Need for exenteration based on orbital or lid involvement determined by the treating surgeon
- Tumor Site: BCC of the HN, not otherwise included in the above; Inclusion criteria: BWH T2b: 2-3 high risk factors. T3: >= 4 high risk features or bone invasion. High risk features include: >= 2 cm, poorly differentiated histology, peak nasal inspiratory (PNI) >= 0.1 mm on biopsy or gross or radiographic perineural invasion, invasion beyond subcutaneous fat
- Male or female, aged >= 18 years of age
- Performance status 0-1
- Must have a life expectancy of at least 6 months as judged by the treating physician
- Absolute neutrophil count 1500/ul or more
- Platelets 100,000/ul or more
- Hemoglobin 9 g/dl or more
- Bilirubin less than or equal to 1.5 x the upper limit of normal (except subjects with Gilbert syndrome, who can have total bilirubin < 3 mg/dl)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 2.5 x the upper limit of normal
- Glomerular filtration rate (GFR) greater than or equal to 40 ml/min using the Cockcroft-Gault formula or measured creatinine clearance using 24 hours urine collection
- Women of reproductive potential should have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]), which must also be confirmed as negative within 28 days of the start of study drugs
- Women of reproductive potential must use highly effective contraception methods to avoid pregnancy for 90 days after the last dose of study drugs. "Women of reproductive potential" is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL
- Men of reproductive potential who are sexually active with women of reproductive potential must use any contraceptive method with a failure rate of less than 1% per year. Men who are receiving the study medications will be instructed to adhere to contraception for 90 days after the last dose of study drugs. Men who are azoospermic do not require contraception
- Informed Consent: All subjects must be able to comprehend and sign a written informed consent document
Exclusion Criteria:
- Prior radiation therapy within the past 6 months for this target cancer documented by surgeon at Visit 1, Day 0 initial assessment. (Prior surgical resection to area/tumor is acceptable)
- Any history of allergy to the study drug components
- Any concurrent malignancies: exceptions include- basal cell carcinoma of the skin at another site, chronic lymphocytic leukemia, melanoma in situ, squamous cell carcinoma of the skin of a secondary location, superficial bladder cancer or in situ cervical cancer that has undergone potentially curative therapy. Patients with a history of other prior malignancy must have been treated with curative intent and must have remained disease-free for 2 years post-diagnosis
- Any unresolved toxicity National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0 Grade >= 2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria. Patients with Grade >= 2 neuropathy will be evaluated on a case-by-case basis after consultation with the Study Physician. Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with anti-PD1 therapy may be included only after consultation with the Study Physician.
- Any Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 28 days of study drug administration., or a prior history of allogenic organ transplantation
- Any diagnosis of a significant connective tissue disorder as determined by the treating surgeon or medical team
- Patients must not be receiving any other investigational agents
- Receipt of a live attenuated vaccine within 30 days prior to the first dose of drug on trial
- Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent
- Patients must not be pregnant or breastfeeding
- Active infection including tuberculosis (TB) (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive hepatitis B virus [HBV] surface antigen [HBsAg] result), hepatitis C, or human immunodeficiency virus [positive HIV 1/2 antibodies]). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc]and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV ribonucleic acid (RNA)
- Any patient with prior immunotherapy or hedge hog inhibitor (HHI) for malignancy treatment
- Any untreated metastasis(es) to the brain that may be considered active
- History of pneumonitis with the past 5 years
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (cemiplimab)
Patients receive cemiplimab IV on study.
Patients undergo CT scans and collection of blood samples throughout the trial.
|
Ancillary studies
Other Names:
Undergo collection of blood samples
Other Names:
Undergo CT scan
Other Names:
Given IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (ORR)
Time Frame: Up to 6 months post surgery (up to Day 309 +/- 3 days)
|
Defined by responders at surgery by clinical assessment and radiographic measurement according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1.
Summarized by frequency counts and percentages and accompanied by exact Clopper-Pearson 95% compatibility intervals (CIs).
|
Up to 6 months post surgery (up to Day 309 +/- 3 days)
|
Disease control rate (DCR)
Time Frame: Up to 6 months post surgery (up to Day 309 +/- 3 days)
|
Defined responders plus stable disease by clinical assessment and radiographic measurement by RECISTv1.1.
Summarized by frequency counts and percentages and accompanied by exact Clopper-Pearson 95% CIs.
|
Up to 6 months post surgery (up to Day 309 +/- 3 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Surgical/Clinical Benefit Rate (SBR)
Time Frame: At surgery (Day 129 +/- 3 days)
|
Percentage of patients with an organ at risk demonstrating tumor response allowing functional organ preservation surgery.
|
At surgery (Day 129 +/- 3 days)
|
Pathologic complete response (pCR)
Time Frame: Up to 6 months post surgery (up to Day 309 +/- 3 days)
|
Pathologic complete response (pCR)
|
Up to 6 months post surgery (up to Day 309 +/- 3 days)
|
Major pathologic response (mPR)
Time Frame: Up to 6 months post surgery (up to Day 309 +/- 3 days)
|
Major pathologic response (mPR)
|
Up to 6 months post surgery (up to Day 309 +/- 3 days)
|
Incidence of adverse events
Time Frame: Up to 6 months post surgery (up to Day 309 +/- 3 days)
|
Incidence of adverse events
|
Up to 6 months post surgery (up to Day 309 +/- 3 days)
|
Changes in quality of life and functional organ preservation (FHNSI)
Time Frame: At baseline (Day 1)
|
Assessed by the Functional Assessment of Cancer Therapy - Head and Neck Symptom Index (FHNSI) validated questionnaires.
Score range: 0-40, higher scores reflect a better outcome.
Summarized with descriptive statistics and plotted graphically (i.e., with box plots).
Those data will be modeled using generalized linear modeling to account for the correlation of the longitudinal observations from the same patient.
|
At baseline (Day 1)
|
Changes in quality of life and functional organ preservation (FACE-Q)
Time Frame: At baseline (Day 1)
|
Assessed by the Functional Assessment of Cancer Therapy Questionnaire (FACE-Q), validated questionnaires.
Score range: 0-100, generally higher scores reflect a better outcome.
Summarized with descriptive statistics and plotted graphically (i.e., with box plots).
Those data will be modeled using generalized linear modeling to account for the correlation of the longitudinal observations from the same patient.
|
At baseline (Day 1)
|
Changes in quality of life and functional organ preservation (VFQ-25)
Time Frame: At baseline (Day 1)
|
Assessed by the Visual Function Questionnaire (VFQ-25) validated questionnaires.
Score range: 0-100, higher scores reflect a better outcome.
Summarized with descriptive statistics and plotted graphically (i.e., with box plots).
Those data will be modeled using generalized linear modeling to account for the correlation of the longitudinal observations from the same patient.
|
At baseline (Day 1)
|
Changes in quality of life and functional organ preservation (FHNSI)
Time Frame: 6 months post-surgery (up to Day 309 +/- 3 days)
|
Assessed by the Functional Assessment of Cancer Therapy - Head and Neck Symptom Index (FHNSI) validated questionnaires.
Score range: 0-40, higher scores reflect a better outcome.
Summarized with descriptive statistics and plotted graphically (i.e., with box plots).
Those data will be modeled using generalized linear modeling to account for the correlation of the longitudinal observations from the same patient.
|
6 months post-surgery (up to Day 309 +/- 3 days)
|
Changes in quality of life and functional organ preservation (FACE-Q)
Time Frame: 6 months post-surgery (up to Day 309 +/- 3 days)
|
Assessed by the Functional Assessment of Cancer Therapy Questionnaire (FACE-Q), validated questionnaires.
Score range: 0-100, generally higher scores reflect a better outcome.
Summarized with descriptive statistics and plotted graphically (i.e., with box plots).
Those data will be modeled using generalized linear modeling to account for the correlation of the longitudinal observations from the same patient.
|
6 months post-surgery (up to Day 309 +/- 3 days)
|
Changes in quality of life and functional organ preservation (VFQ-25)
Time Frame: 6 months post-surgery (up to Day 309 +/- 3 days)
|
Assessed by the Visual Function Questionnaire (VFQ-25) validated questionnaires.
Score range: 0-100, higher scores reflect a better outcome.
Summarized with descriptive statistics and plotted graphically (i.e., with box plots).
Those data will be modeled using generalized linear modeling to account for the correlation of the longitudinal observations from the same patient.
|
6 months post-surgery (up to Day 309 +/- 3 days)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Joseph Curry, MD, Thomas Jefferson University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- iRISID-2022-0944
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Locally Advanced Basal Cell Carcinoma
-
Gruppo Oncologico del Nord-OvestRecruitingLocally Advanced Basal Cell CarcinomaItaly
-
University Hospital, BordeauxCompletedLocally Advanced Basal Cell Carcinoma | Metastatic Basal Cell CarcinomaFrance
-
Sue YomGenentech, Inc.CompletedSkin Cancer | Locally Advanced Basal Cell Carcinoma | Cutaneous MalignancyUnited States
-
Emory UniversityAstex Pharmaceuticals, Inc.RecruitingHead and Neck Carcinoma of Unknown Primary | Locally Advanced Head and Neck Squamous Cell Carcinoma | Locally Advanced Hypopharyngeal Squamous Cell Carcinoma | Locally Advanced Laryngeal Squamous Cell Carcinoma | Locally Advanced Nasopharyngeal Squamous Cell Carcinoma | Locally Advanced Oropharyngeal...United States
-
Memorial Sloan Kettering Cancer CenterRecruitingSkin Cancer | Squamous Cell Carcinoma | Cutaneous Squamous Cell Carcinoma | Locally Advanced Skin Squamous Cell Carcinoma | Locally Advanced Cutaneous Squamous Cell Carcinoma | Locally Advanced Squamous Cell Carcinoma | Locally Advanced Squamous Cell Carcinoma of the SkinUnited States
-
Novartis PharmaceuticalsCompletedAdvanced Solid Tumors | Recurrent or Refractory Medulloblastoma | Locally Advanced or Metastatic Basal Cell CarcinomaUnited States, United Kingdom, Switzerland, Netherlands
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Locally Advanced Bladder Urothelial Carcinoma | Locally Advanced Renal Pelvis Urothelial... and other conditionsUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteGenentech, Inc.RecruitingAdvanced Basal Cell CarcinomaUnited States
-
Mayo ClinicRecruitingMetastatic Lung Non-Small Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Resectable Lung Non-Small Cell Carcinoma | Metastatic Malignant Solid Neoplasm | Metastatic Bladder Urothelial Carcinoma | Metastatic Colorectal Carcinoma | Metastatic Triple-Negative Breast Carcinoma | Locally... and other conditionsUnited States
-
Millennium Pharmaceuticals, Inc.CompletedCarcinoma, Basal Cell | Advanced Nonhematologic MalignanciesUnited States
Clinical Trials on Quality-of-Life Assessment
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol Specific | Malignant NeoplasmUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)RecruitingChildhood Malignant NeoplasmUnited States, Canada, Puerto Rico, Australia, New Zealand
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedOvarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Germ Cell Tumor | Ovarian Sarcoma | Malignant Ovarian Epithelial Tumor | Ovarian Carcinosarcoma | Ovarian Brenner Tumor | Ovarian Mucinous... and other conditionsUnited States
-
Wake Forest University Health SciencesWithdrawnLung Metastases | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma
-
City of Hope Medical CenterNational Cancer Institute (NCI)Recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | COVID-19 InfectionUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | COVID-19 InfectionUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Neuropathy | COVID-19 InfectionUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingCervical Carcinoma | Endometrial Carcinoma | Vaginal Carcinoma | Malignant Female Reproductive System Neoplasm | Vulvar CarcinomaUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 and other conditionsUnited States